α-Synuclein and Parkinson's disease: Selective neurodegenerative effect of α-synuclein fragment on dopaminergic neurons in vitro and in vivo

Annals of Neurology

Volumn 47, Issue 5, 2000, Pages 632-640

  Forloni, Gianluigi ^a   Bertani, Ilaria ^a   Calella, Anna Maria ^a   Thaler, Florian ^a   Invernizzi, Roberto ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FAMILIAL DISEASE; LEWY BODY; MISSENSE MUTATION; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SENILE PLAQUE;

ALPHA-SYNUCLEIN; ANIMALS; CARRIER PROTEINS; CELL AGGREGATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOPAMINE; MALE; MUTATION, MISSENSE; NERVE DEGENERATION; NERVE GROWTH FACTOR; NERVE TISSUE PROTEINS; NEURONS; PARKINSON DISEASE; PEPTIDE FRAGMENTS; PEPTIDES; POINT MUTATION; RATS; SUBSTANTIA NIGRA;

EID: 0034017710     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(200005)47:5<632::AID-ANA11>3.0.CO;2-N     Document Type: Article

References (51)

1. Polimeropoulos MH, Higgins JJ, Golbe LI, et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 1997;274:1197-1199
2. Iwai A, Masliah E, Yoshimoto M, et al. The precursor protein of non Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995; 14:467-475
3. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the a synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047
4. Krüger R, Kuhn W, Müller T, et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat Genet 1998;18:106-108
5. Spillantini MG, Crowter RA, Jakes R, et al. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 1998;95:6469-6473
6. Lippa CF, Fujiwara M, Mann DM, et al. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 1998;153:1365-1370
7. Baba M, Nakajo S, Tu P-H, et al. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 1998;152:879-884
8. Lippa CF, Schmidt ML, Lee VM-Y, et al. Antibodies to α-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann Neurol 1999;45:353-357
9. Masalaha R, Herishanu Y, Alfahel-Kakunda A, et al. Selective dopamine neurotoxicity by an industrial chemical: an environmental cause of Parkinson's disease? Brain Res 1997;774:260-264
10. Kakizuka A. Protein precipitation: a common etiology in neurodegenerative disorders. Trends Genet 1999;14:396-402
11. DiFiglia M, Sapp E, Chase KO, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997;277:1990-1993
12. Brujin LI, Houseweart MK, Kato S, et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1997;281:1851-1854
13. Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant α synuclein linked to early onset Parkinson disease. Nat Med 1998;4:1318-1320
14. Crowther RA, Jakes R, Spillantini MG, et al. Synthetic filaments assembled from c-terminally truncated alpha-synuclein. FEBS Lett 1998;436:309-312
15. Han H, Weinreb PH, Lansbury PT. The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by β amyloid: is NAC a common trigger or target in neurodegenerative disease. Chem Biol 1995;2:163-169
16. Braak H, Sandmann-Keil D, Gai W, et al. Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry. Neurosci Lett 1999;265:67-69
17. Selvaggini C, De Gioia L, Cantù L, et al. Molecular characteristics of a protease-resistant amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. Biochem Biophys Res Commun 1993;194:1380-1386
18. Manthorpe M, Fagnani R, Skaper SD, et al. An automated colorimetric microassay for neurotrophic factors. Dev Brain Res 1986;25:191-198
19. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 2nd ed. Sydney: Academic Press, 1986
20. Invernizzi R, Pozzi L, Bonini I, et al. Effect of amineptine on regional extracellular concentrations of dopamine and noradrenaline in the rat brain. J Pharmacol Exp Ther 1992;262:769-774
21. Smith S, Sharp T. Measurement of GABA in rat brain microdialysates using o-phtaldialdehyde-sulphite derivatization and high performance liquid chromatography with electrochemical detection. J Chromatogr 1994;652:228-233
22. Donzanti BA, Yamamoto BK. An improved and rapid HPLC-EC method for the isocratic separation of amino acid neurotransmitters from brain tissue and microdialysis perfusates. Life Sci 1988;43:913-922
23. Lefevre C, Chol Kang H, Haugland RP, et al. Texas red-X and rhodamine red-X, new derivatives of sulforhodamine 101 and lissamine rhodamine B with improved labelling and fluorescence properties. Bioconjug Chem 1996;7:482-489
24. Yankner BS, Duffy LK, Kirshner DA. Neurotrophic and neurotoxic effects of β-amyloid protein: reversal by tachykinin neuropeptides. Science 1990;250:279-282
25. Forloni G, Chiesa R, Smiroldo S, et al. Apoptosis mediated neurotoxicity induced by chronic application of β amyloid fragment 25-35. Neuroreport 1993;4:523-526
26. Forloni G, Angeretti N, Chiesa R, et al. Neurotoxicity of a prion protein fragment. Nature 1993;362:543-545
27. Mattson MP, Goodman Y. Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium. Brain Res 1995;676:219-224
28. Schubert D, Behl C, Lesley R, et al. Amyloid peptides are toxic via a common oxidative mechanism. Proc Natl Acad Sci USA 1995;92:1989-1993
29. El-Agnaf OM, Jakes R, Curran MD, et al. Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett 1998;440:71-75
30. Mikkelsen JD, Dago L, Olesen OF. Amyloid beta neurotoxicity in the cholinergic but not in the serotonergic phenotype of RN46A cells. Mol Brain Res 1998;57:266-274
31. Quirion R, Kar S, Auld DS. Beta-amyloid peptides as direct cholinergic neuromodulators: a missing link? Trends Neurosci 1998;21:43-49
32. Kowall NW, Beal M, Busciglio J, et al. An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P. Proc Natl Acad Sci USA 1991;88:7247-7251
33. Podinsky M, Stephenson D, Frosc M. Synthetic amyloid β-protein fails to produce specific neurotoxicity in monkey cerebral cortex. Neurobiol Aging 1992;13:561-568
34. Geula C, Wu C-K, Saroff D, et al. Aging renders the brain vulnerable to amyloid β-protein neurotoxicity. Nat Med 1999; 4:827-831
35. Sturchler-Pierrat C, Abramowski D, Duke M, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 1997;94: 13287-13292
36. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 1996;274:99-102
37. Holcomb L, Gordon MN, McGowan E, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 1998;4:97-100
38. Oberdoerster J, Rabin RA. NGF-differentiated and undifferentiated PC12 cells vary in induction of apoptosis by ethanol. Life Sci 1999;64:267-272
39. + neurotoxicity on NGF-differentiated PC12 cells. Cell Biol Int 1995;19:687-693
40. Salmona M, Forloni G, Diomede L, et al. A neurotoxic and gliotrophic fragment of the prion protein increases plasma membrane microviscosity. Neurobiol Dis 1997;4:47-57
41. MacHattle SJ, Brown DR, Bird NM. Cellular uptake of the prion protein fragment PrP106-126 in vitro. J Neurocytol 1999;28:149-159
42. Good TA, Murphy RM. Aggregation state-dependent binding of β-amyloid peptide to protein and lipid components of rat cortical homogenates. Biochem Biophys Res Commun 1995; 207:209-215
43. Mason R, Estermyr J, Kelly J, et al. Alzheimer's disease amyloid β peptide 25-35 is localized in the membrane hydrocarbon core: X-ray diffraction analysis. Biochem Biophys Res Commun 1996;222:78-82
44. Trojanowski JQ, Goedert M, Iwatsubo T, et al. Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death Differ 1998;5:832-837
45. Giasson BI, Uryu K, Trojanowski JQ, et al. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem 1999;274: 7619-7622
46. Wood SJ, Wypych J, Steavenson S, et al. alpha-Synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J Biol Chem 1999;274: 19509-19512
47. Jensen PH, Nielsen MS, Jakes R, et al. Binding of synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J Biol Chem 1998;273:26292-26294
48. van Duinen SG, Lammers GJ, Maat-Schieman ML, et al. Numerous and widespread alpha-synuclein-negative Lewy bodies in an asymptomatic patient. Acta Neuropathol (Berl) 1999;97: 533-539
49. Przedborski S, Jackson-Lewis V. The mechanism of MPTP toxicity. Mov Disord 1998;13(Suppl 1):35-38
50. Scwarting RK, Huston JP. Unilateral 6-hydroxydopamine lesions of mesostriatal dopamine neurons and their physiological sequelae. Prog Neurobiol 1996;49:215-266
51. Perl D, Olanow CW, Calne D. Alzheimer's disease and Parkinson's disease: distinct entities or extremes of a spectrum of neurodegeneration? Ann Neurol 1998;44(Suppl):S19-S31